402 related articles for article (PubMed ID: 22989570)
1. Recombinant human manganese superoxide dismutase reduces liver fibrosis and portal pressure in CCl4-cirrhotic rats.
Guillaume M; Rodriguez-Vilarrupla A; Gracia-Sancho J; Rosado E; Mancini A; Bosch J; Garcia-Pagán JC
J Hepatol; 2013 Feb; 58(2):240-6. PubMed ID: 22989570
[TBL] [Abstract][Full Text] [Related]
2. Terutroban, a TP-receptor antagonist, reduces portal pressure in cirrhotic rats.
Rosado E; Rodríguez-Vilarrupla A; Gracia-Sancho J; Tripathi D; García-Calderó H; Bosch J; García-Pagán JC
Hepatology; 2013 Oct; 58(4):1424-35. PubMed ID: 23703868
[TBL] [Abstract][Full Text] [Related]
3. Resveratrol improves intrahepatic endothelial dysfunction and reduces hepatic fibrosis and portal pressure in cirrhotic rats.
Di Pascoli M; Diví M; Rodríguez-Vilarrupla A; Rosado E; Gracia-Sancho J; Vilaseca M; Bosch J; García-Pagán JC
J Hepatol; 2013 May; 58(5):904-10. PubMed ID: 23262250
[TBL] [Abstract][Full Text] [Related]
4. Tempol administration, a superoxide dismutase mimetic, reduces hepatic vascular resistance and portal pressure in cirrhotic rats.
García-Calderó H; Rodríguez-Vilarrupla A; Gracia-Sancho J; Diví M; Laviña B; Bosch J; García-Pagán JC
J Hepatol; 2011 Apr; 54(4):660-5. PubMed ID: 21159403
[TBL] [Abstract][Full Text] [Related]
5. Metformin reduces hepatic resistance and portal pressure in cirrhotic rats.
Tripathi DM; Erice E; Lafoz E; García-Calderó H; Sarin SK; Bosch J; Gracia-Sancho J; García-Pagán JC
Am J Physiol Gastrointest Liver Physiol; 2015 Sep; 309(5):G301-9. PubMed ID: 26138461
[TBL] [Abstract][Full Text] [Related]
6. Superoxide dismutase gene transfer reduces portal pressure in CCl4 cirrhotic rats with portal hypertension.
Laviña B; Gracia-Sancho J; Rodríguez-Vilarrupla A; Chu Y; Heistad DD; Bosch J; García-Pagán JC
Gut; 2009 Jan; 58(1):118-25. PubMed ID: 18829979
[TBL] [Abstract][Full Text] [Related]
7. PPARα activation improves endothelial dysfunction and reduces fibrosis and portal pressure in cirrhotic rats.
Rodríguez-Vilarrupla A; Laviña B; García-Calderó H; Russo L; Rosado E; Roglans N; Bosch J; García-Pagán JC
J Hepatol; 2012 May; 56(5):1033-1039. PubMed ID: 22245887
[TBL] [Abstract][Full Text] [Related]
8. The anticoagulant rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells.
Vilaseca M; García-Calderó H; Lafoz E; García-Irigoyen O; Avila MA; Reverter JC; Bosch J; Hernández-Gea V; Gracia-Sancho J; García-Pagán JC
Hepatology; 2017 Jun; 65(6):2031-2044. PubMed ID: 28142199
[TBL] [Abstract][Full Text] [Related]
9. Nebivolol treatment increases splanchnic blood flow and portal pressure in cirrhotic rats via modulation of nitric oxide signalling.
Reiberger T; Payer BA; Schwabl P; Hayden H; Horvatits T; Jäger B; Hummel T; Mitterhauser M; Trauner M; Fuhrmann V; Angermayr B; Peck-Radosavljevic M;
Liver Int; 2013 Apr; 33(4):561-8. PubMed ID: 23331709
[TBL] [Abstract][Full Text] [Related]
10. Three-day tetrahydrobiopterin therapy increases in vivo hepatic NOS activity and reduces portal pressure in CCl4 cirrhotic rats.
Matei V; Rodríguez-Vilarrupla A; Deulofeu R; García-Calderó H; Fernández M; Bosch J; Garcia-Pagán JC
J Hepatol; 2008 Aug; 49(2):192-7. PubMed ID: 18534709
[TBL] [Abstract][Full Text] [Related]
11. Leptin receptor blockade reduces intrahepatic vascular resistance and portal pressure in an experimental model of rat liver cirrhosis.
Delgado MG; Gracia-Sancho J; Marrone G; Rodríguez-Vilarrupla A; Deulofeu R; Abraldes JG; Bosch J; García-Pagán JC
Am J Physiol Gastrointest Liver Physiol; 2013 Oct; 305(7):G496-502. PubMed ID: 23886859
[TBL] [Abstract][Full Text] [Related]
12. Amelioration of portal hypertension and the hyperdynamic circulatory syndrome in cirrhotic rats by neuropeptide Y via pronounced splanchnic vasoaction.
Moleda L; Trebicka J; Dietrich P; Gäbele E; Hellerbrand C; Straub RH; Sauerbruch T; Schoelmerich J; Wiest R
Gut; 2011 Aug; 60(8):1122-32. PubMed ID: 21317421
[TBL] [Abstract][Full Text] [Related]
13. Droxidopa, an oral norepinephrine precursor, improves hemodynamic and renal alterations of portal hypertensive rats.
Coll M; Rodriguez S; Raurell I; Ezkurdia N; Brull A; Augustin S; Guardia J; Esteban R; Martell M; Genescà J
Hepatology; 2012 Nov; 56(5):1849-60. PubMed ID: 22610782
[TBL] [Abstract][Full Text] [Related]
14. Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats.
Laleman W; Van Landeghem L; Van der Elst I; Zeegers M; Fevery J; Nevens F
Gastroenterology; 2007 Feb; 132(2):709-19. PubMed ID: 17258737
[TBL] [Abstract][Full Text] [Related]
15. Soluble guanylyl cyclase stimulation and phosphodiesterase-5 inhibition improve portal hypertension and reduce liver fibrosis in bile duct-ligated rats.
Brusilovskaya K; Königshofer P; Lampach D; Szodl A; Supper P; Bauer D; Beer A; Stift J; Timelthaler G; Oberhuber G; Podesser BK; Seif M; Zinober K; Rohr-Udilova N; Trauner M; Reiberger T; Schwabl P
United European Gastroenterol J; 2020 Dec; 8(10):1174-1185. PubMed ID: 32878579
[TBL] [Abstract][Full Text] [Related]
16. Enoxaparin reduces hepatic vascular resistance and portal pressure in cirrhotic rats.
Cerini F; Vilaseca M; Lafoz E; García-Irigoyen O; García-Calderó H; Tripathi DM; Avila M; Reverter JC; Bosch J; Gracia-Sancho J; García-Pagán JC
J Hepatol; 2016 Apr; 64(4):834-42. PubMed ID: 26686269
[TBL] [Abstract][Full Text] [Related]
17. Evidence against a role for NADPH oxidase modulating hepatic vascular tone in cirrhosis.
Gracia-Sancho J; Laviña B; Rodríguez-Vilarrupla A; Brandes RP; Fernández M; Bosch J; García-Pagán JC
Gastroenterology; 2007 Sep; 133(3):959-66. PubMed ID: 17854599
[TBL] [Abstract][Full Text] [Related]
18. Transplantation of endothelial progenitor cells ameliorates vascular dysfunction and portal hypertension in carbon tetrachloride-induced rat liver cirrhotic model.
Sakamoto M; Nakamura T; Torimura T; Iwamoto H; Masuda H; Koga H; Abe M; Hashimoto O; Ueno T; Sata M
J Gastroenterol Hepatol; 2013 Jan; 28(1):168-78. PubMed ID: 22849788
[TBL] [Abstract][Full Text] [Related]
19. Amiloride reduces portal hypertension in rat liver cirrhosis.
Steib CJ; Hennenberg M; Beitinger F; Hartmann AC; Bystron M; De Toni EN; Gerbes AL
Gut; 2010 Jun; 59(6):827-36. PubMed ID: 20551467
[TBL] [Abstract][Full Text] [Related]
20. Comparative portal hypotensive effects as propranolol of vitamin D₃ treatment by decreasing intrahepatic resistance in cirrhotic rats.
Lee PC; Yang YY; Lee WP; Lee KC; Hsieh YC; Lee TY; Lin HC
J Gastroenterol Hepatol; 2015 Mar; 30(3):628-37. PubMed ID: 25187428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]